Released Aug 8, 2024, before the open
10-Q filed Aug 8, 2024, 39 days after period end · 0001628280-24-035867
Q2 2024 · 10-Q
Revenue$6.89M$6.89M +23.0% vs Q2 2023+36.4% vs Q1 2024
Net Income-$22.98M-$22.98M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.45-$0.45 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$26,632,000N/M
Operating Cash Flowderived-$25,537,000N/M
Free Cash Flowderived-$25,554,000N/M
Margins · derived
Operating margin-386.6%+185.8 pt vs Q2 2023
Net margin-333.6%+193.0 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $6.89M | $5.60M | $4.49M | $279.00K |
| Net Income | -$22.98M | -$29.49M | -$27.31M | -$23.11M |
| EPS Diluted | -$0.45 | -$0.70 | -$0.66 | -$0.63 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR